These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 26343386)

  • 1. Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway.
    Shain AH; Garrido M; Botton T; Talevich E; Yeh I; Sanborn JZ; Chung J; Wang NJ; Kakavand H; Mann GJ; Thompson JF; Wiesner T; Roy R; Olshen AB; Gagnon A; Gray JW; Huh N; Hur JS; Busam KJ; Scolyer RA; Cho RJ; Murali R; Bastian BC
    Nat Genet; 2015 Oct; 47(10):1194-9. PubMed ID: 26343386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desmoplastic melanoma: C>Ts and NF-κB.
    Rabbie R; Adams DJ
    Pigment Cell Melanoma Res; 2016 Mar; 29(2):120-1. PubMed ID: 26663830
    [No Abstract]   [Full Text] [Related]  

  • 3. Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations.
    Williams EA; Montesion M; Shah N; Sharaf R; Pavlick DC; Sokol ES; Alexander B; Venstrom J; Elvin JA; Ross JS; Williams KJ; Tse JY; Mochel MC
    Mod Pathol; 2020 Dec; 33(12):2397-2406. PubMed ID: 32483240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational dichotomy in desmoplastic malignant melanoma corroborated by multigene panel analysis.
    Jahn SW; Kashofer K; Halbwedl I; Winter G; El-Shabrawi-Caelen L; Mentzel T; Hoefler G; Liegl-Atzwanger B
    Mod Pathol; 2015 Jul; 28(7):895-903. PubMed ID: 25769001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spitz melanoma is a distinct subset of spitzoid melanoma.
    Raghavan SS; Peternel S; Mully TW; North JP; Pincus LB; LeBoit PE; McCalmont TH; Bastian BC; Yeh I
    Mod Pathol; 2020 Jun; 33(6):1122-1134. PubMed ID: 31900433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Bai X; Kong Y; Chi Z; Sheng X; Cui C; Wang X; Mao L; Tang B; Li S; Lian B; Yan X; Zhou L; Dai J; Guo J; Si L
    Clin Cancer Res; 2017 Oct; 23(20):6120-6127. PubMed ID: 28720667
    [No Abstract]   [Full Text] [Related]  

  • 8. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
    Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
    Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desmoplastic Melanoma Carries High Mutation Burden.
    Cancer Discov; 2015 Nov; 5(11):OF1. PubMed ID: 26432107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.
    van Engen-van Grunsven AC; Küsters-Vandevelde HV; De Hullu J; van Duijn LM; Rijntjes J; Bovée JV; Groenen PJ; Blokx WA
    Gynecol Oncol; 2014 Jul; 134(1):10-4. PubMed ID: 24802725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
    Krauthammer M; Kong Y; Ha BH; Evans P; Bacchiocchi A; McCusker JP; Cheng E; Davis MJ; Goh G; Choi M; Ariyan S; Narayan D; Dutton-Regester K; Capatana A; Holman EC; Bosenberg M; Sznol M; Kluger HM; Brash DE; Stern DF; Materin MA; Lo RS; Mane S; Ma S; Kidd KK; Hayward NK; Lifton RP; Schlessinger J; Boggon TJ; Halaban R
    Nat Genet; 2012 Sep; 44(9):1006-14. PubMed ID: 22842228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells.
    Lidsky M; Antoun G; Speicher P; Adams B; Turley R; Augustine C; Tyler D; Ali-Osman F
    J Biol Chem; 2014 Oct; 289(40):27714-26. PubMed ID: 25063807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.
    Hutchinson KE; Lipson D; Stephens PJ; Otto G; Lehmann BD; Lyle PL; Vnencak-Jones CL; Ross JS; Pietenpol JA; Sosman JA; Puzanov I; Miller VA; Pao W
    Clin Cancer Res; 2013 Dec; 19(24):6696-702. PubMed ID: 24345920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrent KRAS, KIT and SF3B1 mutations in melanoma of the female genital tract.
    Cai YJ; Ke LF; Zhang WW; Lu JP; Chen YP
    BMC Cancer; 2021 Jun; 21(1):677. PubMed ID: 34102999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.
    Cosgarea I; Ugurel S; Sucker A; Livingstone E; Zimmer L; Ziemer M; Utikal J; Mohr P; Pfeiffer C; Pföhler C; Hillen U; Horn S; Schadendorf D; Griewank KG; Roesch A
    Oncotarget; 2017 Jun; 8(25):40683-40692. PubMed ID: 28380455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.
    Mar VJ; Wong SQ; Li J; Scolyer RA; McLean C; Papenfuss AT; Tothill RW; Kakavand H; Mann GJ; Thompson JF; Behren A; Cebon JS; Wolfe R; Kelly JW; Dobrovic A; McArthur GA
    Clin Cancer Res; 2013 Sep; 19(17):4589-98. PubMed ID: 23833303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
    Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
    Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.
    Hintzsche JD; Gorden NT; Amato CM; Kim J; Wuensch KE; Robinson SE; Applegate AJ; Couts KL; Medina TM; Wells KR; Wisell JA; McCarter MD; Box NF; Shellman YG; Gonzalez RC; Lewis KD; Tentler JJ; Tan AC; Robinson WA
    Melanoma Res; 2017 Jun; 27(3):189-199. PubMed ID: 28296713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
    Gao HW; Tsai WC; Perng CL; Wang WM; Chiang CP
    Eur J Dermatol; 2018 Aug; 28(4):509-518. PubMed ID: 30325319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
    Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
    Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.